Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) Shares Outstanding (Diluted Average) (2016 - 2025)

Dare Bioscience (DARE) has disclosed Shares Outstanding (Diluted Average) for 8 consecutive years, with $12.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 49.45% year-over-year to $12.8 million, compared with a TTM value of $12.8 million through Sep 2025, up 49.45%, and an annual FY2024 reading of $8.5 million, up 16.8% over the prior year.
  • Shares Outstanding (Diluted Average) was $12.8 million for Q3 2025 at Dare Bioscience, up from $8.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $85.6 million in Q3 2022 and bottomed at $7.2 million in Q2 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $38.5 million, with a median of $12.8 million recorded in 2025.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 103.23% in 2021, then plummeted 91.5% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $61.2 million in 2021, then soared by 38.29% to $84.6 million in 2022, then crashed by 91.4% to $7.3 million in 2023, then rose by 16.8% to $8.5 million in 2024, then skyrocketed by 50.11% to $12.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for DARE at $12.8 million in Q3 2025, $8.8 million in Q2 2025, and $8.8 million in Q1 2025.